[
  {
    "ts": null,
    "headline": "VIG May Be Poised To Outperform FDVV In 2026",
    "summary": "Compare VIG vs. FDVV ETF performance and explore why Vanguard Dividend Appreciation Index Fund ETF Shares' (VIG) sector focus means 2026 upside.",
    "url": "https://finnhub.io/api/news?id=738e6ba07f0dbdd8905da82974a7cce56d62259f98ce3a74ceff2811f8920e9f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767136961,
      "headline": "VIG May Be Poised To Outperform FDVV In 2026",
      "id": 137945783,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2244450943/image_2244450943.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Compare VIG vs. FDVV ETF performance and explore why Vanguard Dividend Appreciation Index Fund ETF Shares' (VIG) sector focus means 2026 upside.",
      "url": "https://finnhub.io/api/news?id=738e6ba07f0dbdd8905da82974a7cce56d62259f98ce3a74ceff2811f8920e9f"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market",
    "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market. Cheaper generic versions are expected to arrive as early as March next year, and the window to build […]",
    "url": "https://finnhub.io/api/news?id=829926db12641666f4fdeb58c5cb4fda590509845d5d818273b7e3c17ee1fd10",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767136339,
      "headline": "Eli Lilly (LLY) Moves Fast to Secure Lead in India’s Obesity Drug Market",
      "id": 137950164,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE:LLY) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. Eli Lilly and Company (NYSE:LLY) is moving quickly to lock in its position in India’s fast-growing obesity drug market. Cheaper generic versions are expected to arrive as early as March next year, and the window to build […]",
      "url": "https://finnhub.io/api/news?id=829926db12641666f4fdeb58c5cb4fda590509845d5d818273b7e3c17ee1fd10"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China",
    "summary": "Chinese Patients May See More Accessible Obesity Treatments After Pharma Price Moves",
    "url": "https://finnhub.io/api/news?id=aaf583b4001168e5d75c081051b155441a47f53fabb2a324340ac580db5f65cf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767113842,
      "headline": "Eli Lilly and Novo Nordisk Shares Dip After Cut Obesity Drug Prices in China",
      "id": 137941912,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Chinese Patients May See More Accessible Obesity Treatments After Pharma Price Moves",
      "url": "https://finnhub.io/api/news?id=aaf583b4001168e5d75c081051b155441a47f53fabb2a324340ac580db5f65cf"
    }
  },
  {
    "ts": null,
    "headline": "Can Amgen's MariTide Take on Leaders in the Obesity Space?",
    "summary": "AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.",
    "url": "https://finnhub.io/api/news?id=a1a8a5dd8f79cd78f72609ffe69f46f1c8d5e146f44732d4f13c3267259bc1fc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767110700,
      "headline": "Can Amgen's MariTide Take on Leaders in the Obesity Space?",
      "id": 137943085,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "AMGN's MariTide enters late-stage obesity trials with monthly dosing but faces rising competition as Eli Lilly and Novo Nordisk push oral GLP-1s.",
      "url": "https://finnhub.io/api/news?id=a1a8a5dd8f79cd78f72609ffe69f46f1c8d5e146f44732d4f13c3267259bc1fc"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China",
    "summary": "Lower costs aim to expand access in a fast-growing weight-loss market.",
    "url": "https://finnhub.io/api/news?id=7f899b4b7f991d4c2e206316c57a4e822be7173cbe66467b710a2327091b30da",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767106158,
      "headline": "Novo Nordisk and Eli Lilly Slash Obesity Drug Prices in China",
      "id": 137940267,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lower costs aim to expand access in a fast-growing weight-loss market.",
      "url": "https://finnhub.io/api/news?id=7f899b4b7f991d4c2e206316c57a4e822be7173cbe66467b710a2327091b30da"
    }
  },
  {
    "ts": null,
    "headline": "Novo and Lilly cut prices of weight-loss drugs in China",
    "summary": "STORY: Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China.Novo did not give details on the new prices.But media outlet Yicai reported earlier that list prices for the two highest dosages of Wegovy were cut by 48% in some Chinese provinces.The Danish drug maker confirmed a price adjustment to Reuters in a statement.Lilly did not immediately respond to a request for comment.According to a WeChat account for a hospital in the eastern city of Nanjing posted late last week, prices for Lilly's Mounjaro would also decrease from January 1st.Over 65% of China's population of around 1.4 billion could be overweight or obese by 2030.And both drugmakers are competing with rivals in the rapidly growing market.They also face challenges after Novo's patent on Wegovy's active ingredient semaglutide expires in 2026 in China and other important markets.Novo slashed Wegovy prices by up to 37% in India last month, as it seeks to gain ground in another fast-emerging market.Both Novo and Eli Lilly also agreed to cut U.S. prices in November.",
    "url": "https://finnhub.io/api/news?id=1ac46d677bedfed7ca11c0fc1206bebeee8dd7304d4b4f42e21c738308cfe837",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767092939,
      "headline": "Novo and Lilly cut prices of weight-loss drugs in China",
      "id": 137940268,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: Novo Nordisk and Eli Lilly are lowering prices of their top-selling obesity drugs Wegovy and Mounjaro in China.Novo did not give details on the new prices.But media outlet Yicai reported earlier that list prices for the two highest dosages of Wegovy were cut by 48% in some Chinese provinces.The Danish drug maker confirmed a price adjustment to Reuters in a statement.Lilly did not immediately respond to a request for comment.According to a WeChat account for a hospital in the eastern city of Nanjing posted late last week, prices for Lilly's Mounjaro would also decrease from January 1st.Over 65% of China's population of around 1.4 billion could be overweight or obese by 2030.And both drugmakers are competing with rivals in the rapidly growing market.They also face challenges after Novo's patent on Wegovy's active ingredient semaglutide expires in 2026 in China and other important markets.Novo slashed Wegovy prices by up to 37% in India last month, as it seeks to gain ground in another fast-emerging market.Both Novo and Eli Lilly also agreed to cut U.S. prices in November.",
      "url": "https://finnhub.io/api/news?id=1ac46d677bedfed7ca11c0fc1206bebeee8dd7304d4b4f42e21c738308cfe837"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: A Sell As Oral Wegovy Pressures Margins",
    "summary": "Novo Nordiskâs oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO stock a Sell.",
    "url": "https://finnhub.io/api/news?id=144e33292908a226d42cf6af2572b9104d64bf502c1b4be1d6125b96dd8501ab",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767087204,
      "headline": "Novo Nordisk: A Sell As Oral Wegovy Pressures Margins",
      "id": 137939846,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1219304819/image_1219304819.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordiskâs oral Wegovy gets FDA approval, but rising costs and competition threaten profits. Learn why analysts rate NVO stock a Sell.",
      "url": "https://finnhub.io/api/news?id=144e33292908a226d42cf6af2572b9104d64bf502c1b4be1d6125b96dd8501ab"
    }
  },
  {
    "ts": null,
    "headline": "Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge",
    "summary": "Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge",
    "url": "https://finnhub.io/api/news?id=f752fbb288586f34f69cb68d3b21ad7333716e34f31b35d87f17f4fe22ae8529",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767085061,
      "headline": "Biogen: Competing With Eli Lilly's Kisunla, Safety Gives Market Edge",
      "id": 137939607,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f752fbb288586f34f69cb68d3b21ad7333716e34f31b35d87f17f4fe22ae8529"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient",
    "summary": "The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways",
    "url": "https://finnhub.io/api/news?id=1490a6435d29c42798eb12b8047b976244d24afd44f6755e03065b71a4daf84a",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1767057145,
      "headline": "Novo Nordisk's 'long game' on weight loss drugs sparks hope in science, but the Street is impatient",
      "id": 137941555,
      "image": "https://image.cnbcfm.com/api/v1/image/108241956-1765822302147-gettyimages-2177724898-20241010-christo-ozempic-3612.jpeg?v=1765822418&w=1920&h=1080",
      "related": "LLY",
      "source": "CNBC",
      "summary": "The medicine developed by the100-year old Danish drugmaker may impact patients' brains in surprising ways",
      "url": "https://finnhub.io/api/news?id=1490a6435d29c42798eb12b8047b976244d24afd44f6755e03065b71a4daf84a"
    }
  }
]